• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

14.94 +0.42 (+2.89%)
Official Closing Price Updated: 4:15 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,586,891
Open 14.43
Bid (Size) 14.94 (10)
Ask (Size) 15.78 (1)
Prev. Close 14.52
Today's Range 14.33 - 15.31
52wk Range 6.800 - 25.29
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Today 17:00 EDT
From Travere Therapeutics, Inc.
Via Business Wire
7 Analysts Assess Travere Therapeutics: What You Need To Know
June 11, 2025
Via Benzinga

Performance

YTD
-21.2%
-21.2%
1 Month
-28.7%
-28.7%
3 Month
-21.9%
-21.9%
6 Month
-16.6%
-16.6%
1 Year
+103.5%
+103.5%

More News

Read More
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
June 11, 2025
From Travere Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
June 10, 2025
From Pomerantz LLP
Via GlobeNewswire
Earnings Scheduled For May 1, 2025
May 01, 2025
Via Benzinga
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
June 10, 2025
From Travere Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
June 06, 2025
From Pomerantz LLP
Via GlobeNewswire
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
June 03, 2025
From Travere Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
June 02, 2025
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
May 28, 2025
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
May 22, 2025
From Pomerantz LLP
Via GlobeNewswire
Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session
May 16, 2025
Via Benzinga
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why
May 16, 2025
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Top movers in Friday's pre-market session
May 16, 2025
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 16, 2025
Via Benzinga
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
May 16, 2025
Via Benzinga
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries
May 16, 2025
Via Stocktwits
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
May 15, 2025
Via Benzinga
Thursday's after hours session: top gainers and losers
May 15, 2025
Via Chartmill
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
May 15, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
May 13, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
May 07, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Is TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth?
May 02, 2025
Via Chartmill
Travere Therapeutics Reports First Quarter 2025 Financial Results
May 01, 2025
From Travere Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?
Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
What is the current price of Travere Therapeutics, Inc. - Common Stock?
The current price of Travere Therapeutics, Inc. - Common Stock is 14.94
When was Travere Therapeutics, Inc. - Common Stock last traded?
The last trade of Travere Therapeutics, Inc. - Common Stock was at 06/12/25 04:15 PM ET
What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
The market capitalization of Travere Therapeutics, Inc. - Common Stock is 907.11M
How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
Travere Therapeutics, Inc. - Common Stock has 907M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap